Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 209.00
Bid: 208.00
Ask: 215.00
Change: -6.00 (-2.79%)
Spread: 7.00 (3.365%)
Open: 212.00
High: 214.00
Low: 207.00
Prev. Close: 215.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

10 Mar 2020 07:00

RNS Number : 5158F
PureTech Health PLC
10 March 2020
 

10 March 2020

PureTech Health plc

 

Notice of Results

 

PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company") plans to announce its financial results for the year ended 31 December 2019 on Thursday, 9 April 2020.

 

A presentation and conference call for analysts will take place at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will be available on the Company's website at http://puretechhealth.com/investors under the Reports and Presentations tab.

 

PureTech also confirms that the global outbreak of COVID-19 has not adversely affected the Company's business of addressing major diseases through its leadership in immunology and the Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash position and is advancing the business in accordance with its previously announced strategy and timelines while continuing to monitor the situation.

 

About PureTech Health

PureTech is a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's affiliates, is comprised of 23 product candidates and one product that has been cleared by the US Food and Drug Administration (FDA). All of the underlying programmes and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact:

Investors

 

EU media

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

ben.atwell@FTIconsulting.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBCGDXUXGDGGC
Date   Source Headline
29th Aug 20187:00 amRNSNotice of Results
15th Aug 201811:00 amRNSPureTech's Karuna Appoints Steven Paul, MD, as CEO
9th Aug 20187:01 amRNSPureTech's Akili Expands Series C Funding to $68M
2nd Aug 20187:00 amRNSPureTech's Karuna Completes $42M Financing
1st Aug 20185:30 pmRNSTotal Voting Rights
26th Jul 20187:00 amRNSBrain Lymphatics Programme Published in Nature
25th Jul 201812:02 pmRNSPrice Monitoring Extension
25th Jul 201812:01 pmRNSPRTC: resTORbio Announces Positive Topline Results
20th Jul 20187:00 amRNSPRTC & Roche Announce Significant Collaboration
12th Jul 20187:00 amRNSPRTC: resTORbio Notes Publication of Phase 2a Data
10th Jul 20187:00 amRNSPRTC: Vedanta Awarded CCF Funding for IBD Program
27th Jun 20187:00 amRNSAdditional Listing
20th Jun 201812:02 pmRNSPrice Monitoring Extension
19th Jun 20187:05 amRNSPRTC: Karuna Receives $8M Wellcome Trust Award
19th Jun 20187:00 amRNSDirector/PDMR Shareholding
13th Jun 201812:07 pmRNSSecond Price Monitoring Extn
13th Jun 201812:02 pmRNSPrice Monitoring Extension
5th Jun 20187:00 amRNSPRTC: Walgreens CMO joins Gelesis as CMO
30th May 20187:00 amRNSPRTC to Present at Jefferies US Conference
29th May 201812:02 pmRNSPrice Monitoring Extension
25th May 20187:00 amRNSDirector/PDMR Shareholding
22nd May 20187:00 amRNSPRTC Alivio gets key patents for inflammation tech
18th May 20184:45 pmRNSResults of Annual General Meeting
9th May 20187:00 amRNSPRTC?s Akili Raises $55M from Leading Investors
2nd May 20187:00 amRNSPureTech Affiliate Sonde Adds Thai Lee to Board
24th Apr 20187:00 amRNSPureTech Health Appoints Joep Muijrers as CFO
17th Apr 20184:35 pmRNSPrice Monitoring Extension
16th Apr 20187:25 amRNSFinal Results
10th Apr 20187:00 amRNSPRTC Affiliates Granted Key Digital Medicine IP
9th Apr 20188:25 amRNSPRTC's Commense Appoints President and CEO
4th Apr 20187:00 amRNSPRTC's Alivio Tech Published in Leading Journal
3rd Apr 20184:17 pmRNSResult of Meeting
19th Mar 20187:00 amRNSPDMR DEALING - PURCHASE OF SHARES
16th Mar 20187:00 amRNSPDMR DEALING - PURCHASE OF SHARES
15th Mar 20187:00 amRNSPDMR DEALING - PURCHASE OF SHARES
15th Mar 20187:00 amRNSPDMR DEALING - PURCHASE OF SHARES
14th Mar 20187:00 amRNSPDMR DEALING - PURCHASE OF SHARES
14th Mar 20187:00 amRNSPDMR DEALING - PURCHASE OF SHARES
13th Mar 201810:54 amRNSCircular Publication and Notice of General Meeting
13th Mar 20187:35 amRNSResults of Placing
12th Mar 20184:54 pmRNSProposed Placing and Notice of General Meeting
1st Mar 20187:00 amRNSGelesis Raises $30M; Prepares for Potential Launch
20th Feb 20187:00 amRNSTrading Statement
31st Jan 20187:00 amRNSPRTC resTORbio closes IPO, adds $13M to $85M raise
26th Jan 20187:00 amRNSPureTech's resTORbio successfully lists on NASDAQ
3rd Jan 20187:00 amRNSPRTC's resTORbio Adds Senior Biogen Exec to Board
2nd Jan 20187:00 amRNSPRTC's resTORbio Files Public S1 for NASDAQ IPO
19th Dec 20177:00 amRNSLilly to invest $5M in PureTech's Entrega
13th Dec 20177:00 amRNSPureTech's Vedanta Granted Four New US Patents
11th Dec 20177:00 amRNSPureTech's resTORbio Adds Paul Fonteyne to Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.